By
admin
#BIIB, #BIIB analyst estimates, #BIIB analyst recommendations, #BIIB earnings estimates, #BIIB ratings, #BIIB share estimates, #Biogen, #Biogen Inc. analyst estimates, #Biogen Inc. analyst ratings, #Biogen Inc. analyst recommendations, #Biogen Inc. earnings estimates, #Nasdaq, #price, #Quote, #Stock, #U.S
Biogen’s Alzheimer’s Drug Could be Expensive
Biogen (NASDAQ: BIIB) could price its Alzheimer’s drug, Lecanemab, developed along with Essai as high as $20,000 every year, Barron’s reported on Friday, citing data from The Institute for Clinical and Economic Review. The…
Dec. 23, 2022 at 10:14 a.m. ET
on TipRanks.com
